Market Report Focused on Traumatic Brain Injury - Pipeline Review, H2 2016

Traumatic Brain Injury - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Traumatic Brain Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects.

Complete report available @ Traumatic Brain Injury - Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury
- The report reviews pipeline therapeutics for Traumatic Brain Injury by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Traumatic Brain Injury therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Traumatic Brain Injury

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

ALSP, Inc. Amarantus Bioscience Holdings, Inc. Athersys, Inc. Beech Tree Labs, Inc. Cognosci, Inc. Euroscreen S.A. Intellect Neurosciences, Inc. Ischemix, Inc. Karyopharm Therapeutics, Inc. Kyorin Pharmaceutical Co., Ltd. Levolta Pharmaceuticals, Inc. Lixte Biotechnology Holdings, Inc. Lpath, Inc. MandalMed, Inc. Mapreg S.A.S. Neuralstem, Inc. Neuren Pharmaceuticals Limited NeuroNascent, Inc. Neuronax SAS NeuroVive Pharmaceutical AB New World Laboratories, Inc. Novogen Limited NuvOx Pharma LLC Omeros Corporation PharmatrophiX, Inc. Phylogica Limited Prevacus, Inc. QR Pharma, Inc. RegeneRx Biopharmaceuticals, Inc. Remedy Pharmaceuticals, Inc. Sage Therapeutics, Inc. SanBio, Inc. STATegics, Inc. Stemedica Cell Technologies, Inc. SynZyme Technologies, LLC Tetra Discovery Partners LLC Thera Neuropharma Inc vasopharm GmbH VG Life Sciences, Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###